135855-62-8

Basic information

• Product Name: 1H-Indol-6-amine,1-methyl-(9CI)
• Synonyms: 1H-Indol-6-amine,1-methyl-(9CI);6-Amino-1-methylindole;1-Methyl-1H-indol-6-aMine;1H-Indol-6-aMine, 1-Methyl-;(1-Methylindol-6-yl)amine;(1-Methyl-1H-indol-6-yl)amine
• CAS NO: 135855-62-8
• Molecular Formula: C₉H₁₀N₂
• Molecular Weight: 146.192
• Product Categories: AMINEPRIMARY
• Mol File: 135855-62-8.mol

Chemical Properties

• Boiling Point: 328.036°C at 760 mmHg
• Flash Point: 152.191°C
• Appearance: /
• Density: 1.151g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.62
• Storage Temp.: 2-8°C(protect from light)
• PKA: 5.30±0.10(Predicted)
• CAS DataBase Reference: 1H-Indol-6-amine,1-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indol-6-amine,1-methyl-(9CI)(135855-62-8)
• EPA Substance Registry System: 1H-Indol-6-amine,1-methyl-(9CI)(135855-62-8)

Safety Data

• Hazardous Substances Data: 135855-62-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1H-Indol-6-amine,1-methyl-(9CI) is used as a synthetic intermediate in the chemical industry for the preparation of a variety of organic compounds. Its unique structure allows it to be a versatile building block in the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1H-Indol-6-amine,1-methyl-(9CI) is utilized as a precursor for the development of new drugs. Its potential as a pharmacological agent is being explored, particularly in the areas of antiviral and antitumor drug discovery.
Used in Antiviral Applications:
1H-Indol-6-amine,1-methyl-(9CI) is studied for its potential as an antiviral agent, where it may be used to inhibit the replication or infectivity of certain viruses. Its specific antiviral properties are under investigation to determine its efficacy and safety for use in medical treatments.
Used in Antitumor Applications:
1H-Indol-6-amine,1-methyl-(9CI) is also being researched for its possible role in antitumor therapy. It may have the capacity to interfere with the growth or spread of tumors, making it a candidate for further development as a cancer treatment.

InChI:InChI=1/C9H10N2/c1-11-5-4-7-2-3-8(10)6-9(7)11/h2-6H,10H2,1H3

Upstream product

• 475577-34-5 7-benzyloxy-1-methyl-1H-indole 
• 20289-27-4 7-benzyloxyindole 
• 2380-84-9 7-Indolol 
• 475577-33-4 7-hydroxy-1-methyl-1H-indole 
• 4769-96-4 6-nitroindole 
• 99459-48-0 1-methyl-6-nitro-indole 

Downstream Products

• 312299-55-1 3,4,5-trimethoxy-N-(1-methyl-1H-indol-6-yl)benzenesulfonamide 

Relevant articles and documents

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

One-Pot Generation of Benzynes from Phenols: Formation of Primary Anilines by the Deoxyamination of Phenols

Benzynes were selectively generated in situ from phenols and trapped regioselectively with potassium hexamethyldisilazide to form primary anilines following acidic workup. The direct conversion of a phenolic hydroxyl group into a free amino group is a useful method for the preparation of primary aryl amines that are hard to synthesize by using coupling reactions involving phenol derivatives with ammonia. Whereas reactions of ortho- and meta-substituted phenols produced meta-substituted anilines exclusively, those of para-substituted phenols provided ortho-silylanilines.

Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC

Mutated epidermal growth factor receptor (EGFR) is a major driver of non-small cell lung cancer (NSCLC). The EGFRT790M secondary mutation has become a leading cause of clinically-acquired resistance to gefitinib and erlotinib. Herein, we present a structure-based design approach to increase the potency and selectivity of the previously reported reversible EGFR inhibitor 7, at the kinase and cellular levels. Three-step structure-activity relationship exploration led to promising compounds 19e and 19h with unique chemical structure and binding mode from the other third-generation tyrosine kinase inhibitors. In a human NSCLC xenograft model, 19e and 19h exhibited dose-dependent tumor growth suppression without toxicity. These selective inhibitors are promising drug candidates for EGFRT790M-driven NSCLC.

HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions in need of inhibition of heparan sulfate biosynthesis.

NOVEL AMINE DERIVATIVE OR SALT THEREOF

A novel amine derivative expressed by general formula (1) (in the formula: G1, G2, and G3 are the same or different and represent CH or a nitrogen atom; R1 represents a chlorine atom, an optionally-substituted C3-8 cycloalkyl group, or the like; R2 represents -COOR5 (in the formula, R5 represents a hydrogen atom or a carboxyl protective group), or the like; R3 represents a hydrogen atom, or the like; and R4 represents an optionally-substituted condensed bicyclic hydrocarbon group, an optionally-substituted bicyclic heterocyclic group, or the like), or a salt thereof is useful in procedures such as the treatment or prevention of conditions related to excessive keratinocyte proliferation.

THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES

Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF

The present invention provides a diaminopyrimidine derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same, and a use thereof. The diaminopyrimidine derivative or its pharmaceutically acceptable salt functions as a 5-HT4 receptor agonist, and therefore can be usefully applied for preventing or treating dysfunction in gastrointestinal motility, one of the gastrointestinal diseases, such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, or diabetic gastric atony.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Sulphonamide Derivatives

The invention relates to sulphonamide derivatives of formula (I), where RC is optionally substituted 4-6-membered heterocyclic ring containing one or more N atoms, orRC forms together with the phenyl ring to which it is attached a be